The pediatric hereditary angioedema clinic nurse’s communication challenge
Hereditary angioedema affects approximately 1 in 50,000 people, making it one of the rarer conditions seen in pediatric allergy and immunology clinics — rare enough that many families receiving a new diagnosis have never heard of it before, and rare enough that some emergency physicians who encounter an HAE attack do not immediately recognize it. This rarity is itself a communication hazard: unlike Type 1 diabetes, asthma, or sickle cell disease, families managing HAE cannot draw on a community of neighbors and school families who have dealt with the same condition and whose hard-won experience fills in the gaps the clinic did not have time to cover. Every family is starting from near-zero understanding of a disease with some of the most consequential pharmacological mismatches in pediatric medicine.
The central misunderstanding is that HAE looks like allergy. The angioedema — swelling of the lips, tongue, face, hands, genitalia — is clinically identical by appearance to the allergic angioedema that Spanish-speaking families in US emergency departments are more likely to have encountered. The community context reinforces this framing: a child whose tongue is swelling receives a Benadryl and an EpiPen from a family that has watched a relative survive a bee-sting anaphylaxis with exactly those tools. That the mechanism is completely different, the mediator is completely different, and the appropriate treatment is completely different is not intuitive. It requires explicit clinical education. Without it, the treatment reflex for “swelling of face and throat” remains the anaphylaxis reflex, and HAE attacks that reach the larynx have killed patients who were given antihistamines and epinephrine and waited for them to work.
Three features of HAE management create predictable misunderstandings in Spanish-speaking families:
The first is the prophylaxis-success paradox. HAE prophylaxis, when it works, produces attack-free periods that look indistinguishable from disease remission. A family that has not been explicitly taught that the absence of attacks is the proof the medication is working — not the proof it is no longer needed — will eventually conclude that the HAE has resolved, that the medication is unnecessary, and that stopping it is rational. This conclusion is wrong in a way that can be fatal: laryngeal HAE attacks can cause death within two to four hours.
The second is the anaphylaxis toolkit mismatch. HAE attacks and anaphylaxis share the clinical signature of acute angioedema, but HAE is bradykinin-mediated and not histamine-mediated. Diphenhydramine (Benadryl) blocks H1 histamine receptors with zero activity at bradykinin B2 receptors. Epinephrine reverses histamine-driven vasodilation and bronchoconstriction with zero effect on bradykinin production or B2 signaling. A family that reaches for the anaphylaxis kit during an HAE attack is not treating the attack at all — they are administering pharmacologically inert agents and delaying the specific treatment that works. The attack continues to progress.
The third is the abdominal attack blind spot. Most HAE families are educated about facial, extremity, and laryngeal attacks — the most visible and dramatically dangerous manifestations. Abdominal attacks — episodes of severe, spontaneously resolving colicky abdominal pain from bradykinin-driven bowel wall edema — affect 70 to 90 percent of HAE patients and are frequently misdiagnosed as gastrointestinal infections, functional abdominal pain, or surgical emergencies. A family that does not know abdominal pain can be an HAE attack will not use the on-demand HAE medication during these episodes, will not recognize the pattern, and will experience a pattern of avoidable unnecessary ER visits and unnecessary diagnostic workups instead.
Three conversations from the pediatric HAE clinic:
Scenario 1: Sebastián Morales-García — 10 years old, Houston, Texas
Sebastián Morales-García had been diagnosed with hereditary angioedema type I at age eight, two years before this clinic visit. His first recognized attack had been a periorbital swelling over his left eye that his school nurse initially thought was a bee sting or allergic reaction; the swelling had resolved over three days without treatment, and a second episode six weeks later — this time involving his right hand and forearm, lasting two and a half days and resolving fully — prompted his pediatrician to order complement studies. C4 was undetectable. C1-INH antigen was 18 percent of normal. C1-INH functional activity was 12 percent of normal. Genetic sequencing of SERPING1 confirmed a heterozygous frameshift mutation at exon 7, a loss-of-function variant consistent with HAE type I.
He had been referred to the pediatric allergy and immunology clinic at Texas Children’s Hospital. After a full evaluation, he had been started on Haegarda — subcutaneous C1 esterase inhibitor 60 units per kilogram, administered twice weekly at home by his father — as long-term prophylaxis. He had also been prescribed icatibant (Firazyr) auto-injectors as on-demand acute treatment for breakthrough attacks. The first eight months on Haegarda had been remarkable: zero attacks. Sebastián, who had previously missed nine school days in the six months before diagnosis due to swelling episodes, had a perfect attendance semester.
His father, Rodrigo Morales-Torres, a construction supervisor who managed a crew of fourteen workers and who was accustomed to solving problems systematically, had been the primary caregiver managing the twice-weekly subcutaneous injections. He had been initially skeptical that a ten-year-old needed twice-weekly injections indefinitely for a condition that “went away on its own” each time. By month eight, his skepticism had deepened into a conviction: eight months without a single attack meant the HAE had resolved, or at minimum had significantly reduced in severity. He had looked online and read that some patients “go into remission.” He had written a note in the family calendar: “8 meses sin ataques — ¿seguir con Haegarda?” He discussed the question with his wife, and they agreed: the medication was working so well it seemed unnecessary. He stopped the injections.
He did not call the clinic. He had an appointment scheduled in six weeks and intended to raise the question then. He believed stopping a preventive medication during a period of no symptoms was no different from stopping a vitamin he had not needed that winter.
Fourteen weeks after stopping Haegarda, Sebastián had an attack. It began as a tingling around his lips on a Wednesday afternoon after a particularly stressful week of end-of-term school exams. Within two hours, his upper lip had swollen to twice its normal size. By hour four, his tongue was visibly enlarged. Rodrigo gave him the icatibant auto-injector, which he had kept at home. The tongue swelling began to improve over the next four hours, but the lip swelling persisted. They went to the Texas Children’s ED for observation. He was admitted overnight for airway monitoring. His discharge complement studies: C4 undetectable, confirming active contact pathway activity. A call to the HAE clinic the following morning resulted in an urgent visit with nurse Carmen García-Torres.
Carmen had been the HAE clinic nurse for seven years and had navigated the prophylaxis-cessation conversation many times. She sat with Rodrigo and his wife and began with the question he had not asked: “¿Por qué cree que los ocho meses sin ataques significan que el HAE mejoró?” (Why do you think the eight months without attacks mean the HAE improved?) Rodrigo answered honestly: because if the attacks had stopped, something must have changed. Carmen affirmed the logic before correcting the biology: the instinct to interpret absence of symptoms as absence of disease is correct in most medical contexts. It is wrong in HAE, and here is why.
The SERPING1 gene is present in every cell in Sebastián’s body, she explained. The frameshift mutation in one copy of that gene produces either a truncated C1-INH protein that is degraded before reaching the bloodstream, or a non-functional C1-INH protein that cannot inhibit Factor XIIa and plasma kallikrein. The net result: Sebastián’s blood contains approximately 15 to 20 percent of the normal C1 esterase inhibitor activity — too little to reliably suppress the contact activation pathway when it is triggered. Haegarda — plasma-derived C1 esterase inhibitor, subcutaneous formulation — provides supplemental C1-INH into the bloodstream. The 60 units per kilogram twice weekly maintains plasma C1-INH activity at levels sufficient to suppress the kallikrein-kinin cascade below the threshold needed to generate bradykinin in concentrations that cause angioedema. The mechanism: C1-INH binds to and inactivates activated Factor XII and plasma kallikrein, forming covalent inhibitor-protease complexes that are cleared from the circulation. With adequate C1-INH activity, kallikrein cannot cleave enough high-molecular-weight kininogen to produce bradykinin in angioedema-inducing concentrations. No bradykinin accumulation. No B2 receptor activation. No vascular permeability increase. No swelling. Eight months without attacks.
Carmen paused here for Rodrigo: “Los ocho meses sin ataques son la prueba de que el Haegarda estaba frenando el sistema. No son la prueba de que el sistema ya no necesita ser frenado.” (The eight months without attacks are the proof that the Haegarda was braking the system. They are not the proof that the system no longer needs to be braked.) She used an analogy Rodrigo understood immediately: a construction site where a water main runs under the work zone. You install a pressure valve to prevent the water main from rupturing under excavation stress. Six months with no rupture does not mean the water main is no longer under pressure — it means the pressure valve is doing its job. Removing the valve removes the protection.
The SERPING1 mutation, Carmen continued, was inherited from Sebastián’s paternal uncle, who had been diagnosed with HAE at age 35 after two decades of unexplained swelling episodes. The mutation was present before Sebastián was born and would be present in his cells for the rest of his life. HAE does not improve with age during childhood — in fact, hormonal changes during puberty often intensify attack frequency and severity, which is why the clinical team had chosen prophylaxis at diagnosis rather than waiting. The gene cannot be modified by any available therapy. The C1-INH deficiency is permanent. The only thing that changes with prophylaxis is whether there is sufficient C1-INH activity in the bloodstream at any given moment to suppress the contact pathway. Stopping prophylaxis removes that activity within the half-life of the drug — for subcutaneous C1-INH, roughly 48 to 72 hours — and the contact pathway resumes running unrestrained. The kallikrein-bradykinin cascade returns to its uninhibited state. Attacks return, triggered by the same stressors as before — emotional stress, physical exertion, infections, dental procedures.
She explained what had likely happened over the fourteen weeks after stopping Haegarda. For the first four to eight weeks, Sebastián may have had residual contact pathway suppression from the Haegarda already in his system, or he had simply not encountered a strong enough trigger. By weeks eight through fourteen, his contact pathway was fully unrestrained again and his exposure to stress — specifically end-of-year exams — was sufficient to trigger the cascade. The attack on Wednesday afternoon was not coincidence: emotional stress is one of the most consistent HAE triggers documented in the literature, operating through adrenergic pathways that increase contact pathway activation.
Before the visit ended, Carmen and the physician restarted Haegarda at the same dose and reviewed the icatibant protocol. She gave Rodrigo a printed sheet in Spanish titled “Por qué los meses sin ataques significan que el medicamento funciona” (Why attack-free months mean the medication is working) — a one-page explanation designed for the specific conversation he had had in his own kitchen eight weeks earlier. She also scheduled a three-month follow-up rather than the usual six-month interval, giving Rodrigo specific numerical targets: if C4 remains undetectable and C1-INH functional activity remains below 20 percent at that visit, the Haegarda is confirmed as necessary and the conversation is closed.
Scenario 2: Valentina Torres-Espinoza — 8 years old, San Antonio, Texas
Valentina Torres-Espinoza had been diagnosed with HAE type I at age six, after her pediatrician recognized a pattern of non-urticarial, non-pruritic swelling episodes in a child whose father — discovered incidentally through Valentina’s complement workup — had HAE that had been undiagnosed for thirty years, attributed to recurring gastrointestinal infections and seasonal allergies. Her complement panel: C4 low-normal, C1-INH antigen 22 percent of normal, C1-INH functional activity 19 percent of normal. SERPING1 sequencing confirmed a heterozygous splice-site mutation in intron 4, same variant present in her father Luis Torres-Cisneros’s family.
Valentina was on no long-term prophylaxis — she had had two mild attacks in the two years since diagnosis, both involving her right hand and resolving within two days without on-demand treatment, and the clinical team’s assessment was that her current attack burden did not meet the threshold for prophylaxis initiation (fewer than two significant attacks per year causing meaningful disability or school absence). She had been prescribed icatibant auto-injectors at home and school. The family had attended a one-hour HAE education session with nurse María Torres-García and the immunologist at the time of diagnosis. Luis, who had also been started on evaluation and mild prophylaxis through the adult HAE clinic, had become an engaged patient advocate — he had read extensively about HAE online, had joined an online HAE patient community, and had created detailed emergency protocols for Valentina’s school nurse.
His emergency protocol for the school nurse included: diphenhydramine 25 mg by mouth at onset of swelling; EpiPen Jr subcutaneous if swelling spreads to face; call father immediately; call 911 if breathing is affected. The school nurse had this protocol on file. Luis had created it based on his reading of allergic reaction emergency management — he understood, correctly, that his protocol was appropriate for anaphylaxis, and he had not understood, incorrectly, that HAE requires an entirely different protocol because it is not anaphylaxis.
On the day of the attack, Valentina was at an outdoor physical education class. She had been working on a science project presentation and was visibly anxious about it. During the class, she developed tingling and mild swelling of her right hand. Her teacher notified the school nurse, who — following the protocol Luis had created — gave Valentina 25 mg of diphenhydramine by mouth. Luis was called. He arrived at school forty-five minutes after the call. By that time the swelling had progressed from the right hand to the right forearm, despite the diphenhydramine. Luis checked the time: the Benadryl had had forty-five minutes to work. He noted the swelling was worse, not better. He concluded that the dose had not been sufficient. He administered the EpiPen Jr into Valentina’s outer thigh. He waited.
Two hours after the epinephrine, the swelling had progressed further — now involving the right upper arm, and beginning in the right side of the face. Luis was troubled. He called the immunologist’s office but was told the next available callback would be an hour. He decided to wait another forty-five minutes to see if the epinephrine would take full effect. The icatibant auto-injectors were in Valentina’s backpack. He had not reached for them because he was following the protocol he knew: antihistamine first, then epinephrine, then ER if no improvement. The icatibant was the third-tier option he did not yet fully believe in — he had been told it was available but the concept of a bradykinin antagonist was unfamiliar, and the Benadryl-EpiPen sequence was the intervention he trusted from his own lifelong experience with the allergy system.
Six hours after the attack began, Luis brought Valentina to University Hospital’s pediatric ED with swelling involving her entire right arm, right face, and beginning lip and tongue thickening. He handed the triage nurse the emergency protocol he had created. The attending immunologist on call recognized immediately that Valentina was having an HAE attack, not an anaphylactic reaction. The distinction: non-urticarial, non-pruritic swelling developing over six hours, no hives, no bronchospasm, no hypotension, pattern consistent with prior HAE attacks, family history of HAE type I, complement C4 undetectable on point-of-care draw. Icatibant 0.3 mg subcutaneous was administered at the ED. Within six hours, the tongue swelling had reduced. Within twenty-four hours, all swelling had resolved. Valentina was discharged the following afternoon.
María Torres-García met with Luis two days later for an urgent HAE education follow-up. The meeting began, as Carmen’s had, with an acknowledgment that his emergency protocol had been rational given his frame of reference: he had used the best-known allergy emergency tools available. The error was not in his response time or his attention to his daughter — it was in the framework he was applying. HAE and anaphylaxis look identical from the outside. The mechanisms are entirely different. And the treatment mismatch is not “suboptimal” — it is pharmacologically inert.
María explained the mechanism from first principles. Anaphylaxis begins with IgE. A sensitized mast cell carries IgE antibodies on its surface. When the allergen arrives, it cross-links two or more IgE molecules, triggering the mast cell to release its contents: histamine, tryptase, prostaglandin D2, leukotriene C4, platelet-activating factor. Histamine binds H1 receptors on blood vessels and airway smooth muscle, causing vasodilation and bronchoconstriction. The swelling in anaphylaxis is histamine-driven. Diphenhydramine blocks H1 receptors — it competes with histamine for receptor binding, reversing the receptor activation. It works. Epinephrine binds alpha-1 adrenergic receptors on vascular smooth muscle, causing vasoconstriction that directly counteracts the histamine-driven vasodilation, and beta-2 adrenergic receptors on bronchial smooth muscle, causing bronchodilation. It works. These are the right tools for the right mechanism.
HAE has no IgE. No mast cell is involved. No histamine is released. The cascade is entirely different: the contact activation pathway, running through Factor XII and plasma kallikrein, generates bradykinin by cleaving high-molecular-weight kininogen. Bradykinin binds bradykinin B2 receptors on the vascular endothelium — these are G-protein-coupled receptors coupled to Gq signaling, completely distinct from H1 receptors. B2 receptor activation stimulates phospholipase C and increases intracellular calcium, activating endothelial nitric oxide synthase and producing nitric oxide and prostacyclin. These signaling molecules cause endothelial cell cytoskeleton remodeling, junctional protein dissociation, and the opening of paracellular gaps between endothelial cells. Plasma leaks through these gaps into the tissue interstitium: angioedema. Diphenhydramine: no affinity for B2 receptors. Cannot block bradykinin binding. Cannot reduce the endothelial signaling. Pharmacologically inert in this context. Epinephrine: no effect on kallikrein activity, no effect on bradykinin generation, no effect on B2 signaling. Also pharmacologically inert.
María then explained icatibant. It is a synthetic decapeptide that is a competitive antagonist at the bradykinin B2 receptor — it binds the same receptor that bradykinin binds, with high affinity, blocking bradykinin from activating it. Without B2 receptor activation, the endothelial signaling cascade stops. Nitric oxide and prostacyclin production decrease. Junctional proteins reassemble. Paracellular gaps close. Plasma stops leaking. The edema does not resolve instantly — the fluid already in the tissue must reabsorb, which takes hours — but the progression stops and the existing edema gradually resolves. Icatibant is the right tool for the right mechanism. It should be used at the first sign of an HAE attack, not as a third-line option after two ineffective treatments have been tried for six hours.
She revised the emergency protocol with Luis in real time. The new protocol: at first sign of HAE swelling (tingling, tightness, any visible edema), administer icatibant subcutaneously, call the HAE clinic line, go to the nearest ED. No Benadryl. No EpiPen. These are not part of HAE emergency management. She wrote this explicitly in bold on the new protocol sheet: “BENADRYL Y EPIPEN NO SON EFECTIVOS EN EL HAE — NO SE USAN PARA ATAQUES DE HAE.” (BENADRYL AND EPIPEN ARE NOT EFFECTIVE IN HAE — THEY ARE NOT USED FOR HAE ATTACKS.) The icatibant is the first intervention, always. And tongue or throat swelling — any swelling in the midline, any change in voice quality, any sensation of throat tightness — means ER simultaneous with icatibant administration, no waiting at home.
Scenario 3: Diego Hernández-Cisneros — 12 years old, Dallas, Texas
Diego Hernández-Cisneros had been diagnosed with HAE type I at age ten, during a family cascade screening triggered by his paternal uncle’s HAE diagnosis. His complement panel confirmed the diagnosis: C4 undetectable, C1-INH antigen 19 percent of normal, C1-INH functional activity 16 percent of normal. The family history on the paternal side included the uncle, the uncle’s mother (Diego’s paternal grandmother), and a paternal great-aunt who had died in her forties from a sudden respiratory illness that the family now believed was an unrecognized laryngeal HAE attack in the era before specific HAE treatments were available.
Diego had been started on long-term prophylaxis with lanadelumab (Takhzyro) 300 mg subcutaneous every four weeks, given the strong family history including a probable death from laryngeal HAE. He had been prescribed icatibant as on-demand acute treatment. He had attended the initial HAE education session with his mother Elena Hernández-Torres, a middle school teacher, and his father. Elena had taken careful notes. The education session had focused on facial and laryngeal attacks — the clinical team had emphasized recognizing throat tightness and tongue swelling as emergencies, and had demonstrated the icatibant injection technique.
What the education session had not covered explicitly — or had covered too briefly for the family to retain — was abdominal attacks. Elena’s notes from the session had one line about abdominal involvement: “HAE puede afectar el abdomen.” (HAE can affect the abdomen.) No description of what an abdominal attack felt like, how long it lasted, how to recognize it, or that icatibant was appropriate treatment for it.
Over the twelve months following diagnosis, Diego had five episodes that fit the following pattern: sudden onset severe periumbilical and lower abdominal cramping pain, rating 7 to 9 out of 10 in severity; nausea; two to three episodes of vomiting; watery diarrhea beginning on day two; complete spontaneous resolution by day three to five; no fever; no diarrhea at onset. The first episode occurred three months after diagnosis. Elena took Diego to a Children’s Health urgent care in Dallas. The urgent care physician, noting the absence of fever and the colicky pattern, diagnosed “acute gastrointestinal illness, likely viral” and sent Diego home with instructions to push fluids. The second episode occurred at month five. Elena took Diego to a different ER. The examining physician ordered a complete blood count (leukocyte count 13,400, consistent with stress leukocytosis), a urine analysis, and an abdominal ultrasound (mild bowel wall thickening at the terminal ileum, no appendiceal abnormality). Diagnosis: “mesenteric lymphadenitis versus viral gastroenteritis.” Sent home.
The third episode occurred at month eight. This time, Diego’s pain was 9 out of 10, he was doubled over, and the abdominal guarding on physical examination was significant. A pediatric surgery consult was obtained. The surgeon palpated the abdomen, reviewed the ultrasound, and recommended CT with contrast to rule out early appendicitis. CT showed bowel wall thickening in multiple small bowel segments and a small amount of free peritoneal fluid. No appendiceal abnormality. Surgical diagnosis: “acute abdomen, probably infectious or inflammatory, no surgical indication. Observe for 24 hours.” The pain resolved spontaneously over 36 hours. Diego was discharged.
It was not until the fourth episode, when Elena brought Diego to Children’s Medical Center Dallas and happened to mention “he has hereditary angioedema” in the triage assessment, that a pediatric emergency physician connected the pattern. She consulted the pediatric allergy and immunology fellow on call, who reviewed the prior four episodes and recognized immediately: five episodes of severe spontaneously-resolving colicky abdominal pain with bowel wall thickening on imaging and no infectious etiology identified, in a child with known C1-INH deficiency — this was the textbook presentation of HAE abdominal attacks. Icatibant 0.3 mg subcutaneous was administered. The pain score fell from 9 out of 10 to 3 out of 10 within four hours. Diego was discharged home on pain management the following morning.
Nurse Ana Cisneros-Espinoza met with Elena at the HAE clinic follow-up visit the following week. Elena’s first words were: “¿Por qué nadie nos dijo?” (Why did nobody tell us?) Ana acknowledged the legitimate frustration: the family had attended the education session, they had managed Diego’s medications correctly, they had gone to the ER appropriately, and yet five episodes of HAE abdominal attacks had resulted in five unnecessary ER visits, an unnecessary CT scan with radiation exposure, an unnecessary surgical consultation, and Diego missing approximately twelve school days over twelve months — all of which could have been prevented or dramatically shortened with icatibant administered at home at onset.
Ana explained the mechanism of HAE abdominal attacks. The mesenteric blood vessels that supply the small bowel, stomach, and colon express bradykinin B2 receptors on their vascular endothelium, identical to the B2 receptors on facial and extremity blood vessels. When the contact activation cascade is triggered, bradykinin is generated systemically — it circulates in the bloodstream and reaches all endothelial B2 receptors, not only the ones in the face or hands. If the B2 receptors in the mesenteric circulation receive a bradykinin signal, the bowel wall submucosa becomes edematous — plasma extravasates from the submucosal capillaries into the submucosal tissue and the bowel wall thickens. The bowel is exquisitely pain-sensitive when its wall is distended; the resulting pain is severe, colicky, and episodic, similar in character to partial bowel obstruction. If significant plasma extravasation occurs from the peritoneal serosa, free fluid accumulates in the peritoneal space — the finding the CT had shown.
The clinical signature of HAE abdominal attacks, Ana continued, is the spontaneous complete resolution. A bowel obstruction does not resolve spontaneously. A perforated appendix does not resolve spontaneously. Mesenteric ischemia does not resolve spontaneously. HAE abdominal attacks resolve spontaneously because bradykinin has a very short biological half-life — approximately 17 seconds in plasma, inactivated rapidly by angiotensin-converting enzyme (kininase II) in the pulmonary and endothelial circulation — and once the contact pathway trigger subsides and bradykinin clears, the endothelial junctions reseal, the capillary leak stops, and the submucosal edema gradually reabsorbs over 24 to 72 hours. The body resolves the attack on its own. The five episodes that resolved spontaneously in two to five days were HAE attacks resolving on their own timeline, not gastrointestinal infections clearing.
Ana explained why icatibant is the appropriate treatment for abdominal attacks, and why the family should not need to make a pharmacological distinction between a facial attack and an abdominal attack. Icatibant is a bradykinin B2 receptor antagonist. B2 receptors are present throughout the vasculature. Whether bradykinin is activating B2 receptors in the face, the hand, or the bowel, icatibant blocks the receptor. The treatment is the same. The dose is the same. The administration is the same. The family’s mental model of HAE should be extended: HAE does not only swell the face and throat. It swells any tissue that has B2-receptor-expressing blood vessels when bradykinin is generated. The face, the hands, the genitalia, the feet, the larynx — and the inside of the abdomen. The abdomen swells from the inside, which is why it looks nothing like facial edema from the outside but is the same disease at the cellular level.
Ana walked Elena through the revised action plan. If Diego develops sudden severe abdominal pain — especially if it is periumbilical, colicky, severe enough that he rates it above 6 out of 10, and not explained by a concurrent fever or recent food exposure — the family should first verify that there are no simultaneous signs of laryngeal involvement (throat tightness, voice change, stridor), administer icatibant subcutaneous at home, and call the HAE clinic line. If the pain is rapidly worsening, if laryngeal signs are present, or if Diego is vomiting and cannot tolerate observation at home, they should go to the ED simultaneously with icatibant administration, bringing the HAE emergency card explaining to the ER team that this child has HAE type I, that the appropriate on-demand treatment is icatibant or C1-INH concentrate, and that the presentation is consistent with an HAE abdominal attack. The critical point, Ana emphasized: an abdominal HAE attack and a facial or laryngeal HAE attack are the same disease at the molecular level. Treating one and not recognizing the other as HAE means that half of Diego’s attacks are going untreated.
There was one additional safety teaching that Ana delivered deliberately: the relationship between abdominal attacks and laryngeal attacks. They are not entirely independent. In a subset of patients, laryngeal attacks and abdominal attacks occur within the same attack episode or in rapid sequence — the contact pathway activation that generated enough bradykinin to cause bowel wall edema may also generate enough bradykinin to begin laryngeal edema. A patient who is at home riding out an abdominal attack over two to three days and develops progressive throat tightness or voice changes may have only one to two hours before laryngeal obstruction becomes life-threatening. Elena should know: if during any abdominal pain episode Diego develops any throat symptoms, the response is 911 and the ER, not waiting to see if the abdominal attack and the throat symptom are related.
Key Spanish phrases for the pediatric HAE clinic
For the conversation about prophylaxis and attack-free periods: “Los meses sin ataques significan que el medicamento preventivo está funcionando. No significan que el HAE desapareció ni que ya no necesita el medicamento.” (The months without attacks mean the preventive medication is working. They do not mean the HAE disappeared or that it no longer needs the medication.) “El HAE es causado por un gen que Sebastián heredará siempre. No se cura con el tiempo. El medicamento preventivo frena el sistema que produce la hinchazón — cuando lo paramos, ese sistema se reactiva.” (HAE is caused by a gene Sebastián will always have. It does not cure with time. The preventive medication brakes the system that produces the swelling — when we stop it, that system reactivates.)
For the conversation about why Benadryl and EpiPen do not work: “El HAE no es una alergia. La hinchazón del HAE viene de una sustancia diferente a la histamina. El Benadryl bloquea la histamina — no tiene efecto sobre la sustancia que produce la hinchazón del HAE.” (HAE is not an allergy. HAE swelling comes from a different substance than histamine. Benadryl blocks histamine — it has no effect on the substance that produces HAE swelling.) “El EpiPen tampoco funciona para el HAE. El mecanismo del HAE no involucra histamina ni los receptores donde actúa la adrenalina.” (The EpiPen also does not work for HAE. The mechanism of HAE does not involve histamine or the receptors where adrenaline acts.) “Si Valentina tiene un ataque de HAE y usted le da Benadryl o EpiPen, el ataque va a seguir empeorando. El medicamento correcto para los ataques de HAE es el icatibant — eso sí actúa sobre el mecanismo del HAE.” (If Valentina has an HAE attack and you give her Benadryl or EpiPen, the attack will keep worsening. The correct medication for HAE attacks is icatibant — that one does act on the HAE mechanism.)
For the conversation about abdominal attacks: “El HAE también puede causar ataques dentro del abdomen — hinchazón de la pared del intestino que produce un dolor muy fuerte que mejora solo en dos a cinco días. Eso es un ataque de HAE en el abdomen, no una infección.” (HAE can also cause attacks inside the abdomen — swelling of the intestinal wall that produces very severe pain that resolves on its own in two to five days. That is an HAE attack in the abdomen, not an infection.) “El icatibant funciona igual para los ataques de barriga que para los ataques de cara. Si Diego tiene un dolor de barriga fuerte y sin fiebre que tiene ese patrón, use el icatibant.” (Icatibant works equally for belly attacks as for face attacks. If Diego has severe abdominal pain without fever following that pattern, use the icatibant.)
For emergency warning signs: “Si la lengua, la boca, o la garganta empiezan a hincharse — o si la voz cambia, suena ronca, o si siente que algo le aprieta la garganta — eso es una emergencia. Use el icatibant inmediatamente y vaya a urgencias al mismo tiempo. No espere.” (If the tongue, mouth, or throat starts to swell — or if the voice changes, sounds hoarse, or if she feels something tightening in the throat — that is an emergency. Use icatibant immediately and go to the emergency room at the same time. Do not wait.) “Lleve siempre la tarjeta de emergencia del HAE a urgencias. Enséñela en el triage. Dice que el HAE no responde al Benadryl ni al EpiPen y que el tratamiento específico es el icatibant o el C1 inhibidor.” (Always bring the HAE emergency card to the emergency room. Show it at triage. It says that HAE does not respond to Benadryl or EpiPen and that the specific treatment is icatibant or C1 inhibitor.)